Reassessing the prevalence of monophasic, polyphasic and persistent disease courses in still’s disease
Authors' conclusion
Drug-free remissions in chronic, non-monophasic Still's disease may be more common than previously demonstrated. In the age of IL-1 and IL-6 inhibitors, a monophasic disease course may be more prevalent.
Study context
- Population
- Patients diagnosed with Still's disease (sJIA) between 1998–2021, minimum follow-up 1 year, 3 hospitals in Israel and 2 in the USmedian follow-up 2.8 years (1.1–17)
- Participants
- 82 patients
- Exposure
- Disease course in Still's disease diagnosed before 2012 vs 2012 or later
- 2012 or latern = 59
- Outcome
- Disease course: monophasic, polyphasic or chronic-persistent
Methodological detailsmulticentre, retrospective chart review, 3 hospitals in Israel and 2 in the US
- Multicentre
- Retrospective chart review
- 3 hospitals in Israel and 2 in the US
Main finding
As reported in the abstract
Disease course (whole cohort)
Monophasic
34.1%
Polyphasic (higher than expected)
46.3%
Persistent
19.5%
Observational data: associations, not effects.
Further findings
Non-monophasic (polyphasic or persistent) disease by diagnosis era · not statistically significant
P = 0.22
| Outcome | OR (CI) | P value | |
|---|---|---|---|
| Predictor of non-monophasic course: active disease 3 months from diagnosis (multivariate logistic regression)Active disease at 3 monthsvs No active disease at 3 monthsIndependent risk factor | 4.16 (1.33–15.2) | P = 0.02 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Reassessing the prevalence of monophasic, polyphasic and persistent disease courses in still’s disease. Semin Arthritis Rheum. Published 22 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →